- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06217406
Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes (PTH2) (PTH2)
Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes Simplex Virus Oropharyngeal Reactivation and One or Less Organ Failure
This research aims to assess the interest of preemptive treatment with Acyclovir in mechanically ventilated patients with reactivation of Herpes simplex (HSV) in the throat and failure of one organ or less. HSV reactivation is common in patients hospitalized in an intensive care unit (ICU) on invasive mechanical ventilation. It begins at the oropharyngeal level (incidence up to 20-50%), then progresses downward with contamination of the distal airways (reported incidence of 20-65%). HSV reactivation is associated with high mortality. The investigators aim to disable that, in mechanically ventilated patients with HSV reactivation in the throat and failure of one organ or less, preemptive treatment with Acyclovir may reduce mortality.
To answer the question posed in the research, it is planned to include 246 people hospitalized in intensive care on invasive mechanical ventilation, presenting with HSV reactivation of the throat and one organ failure or less.
Study Overview
Status
Intervention / Treatment
Detailed Description
Herpes simplex virus (HSV) reactivations are frequent in intensive care unit (ICU) patients receiving invasive mechanical ventilation. HSV reactivation first occurs in the throat (incidence up to 20-50%), then progress through a descending way with HSV reactivation in the lung (incidence reported from 20-65%). In some patients, a true HSV bronchopneumonitis can occur: in a prospective study, Luyt et al. found that 24% of patients ventilated for more than 4 days and having ventilator-associated pneumonia suspicion had HSV bronchopneumonitis. These reactivations have been associated with increased mortality, which could be explained by the virus-induced injury on the lung parenchyma, by the increased rate of bacterial pneumonia associated with viral infection, or by the prolongation of mechanical ventilation induced by the previous factors. However, to date it is still unknown if HSV is really a pathogen with its own morbidity/mortality, or only a bystander (with reactivation occurring preferentially in the most severe patients). The only way to know whether or not HSV reactivation has an attributable mortality is to show that a specific treatment, namely acyclovir, has an impact on mortality. One recent randomized controlled study, the PTH study, found that preemptive acyclovir treatment was not associated with shorter duration of mechanical ventilation, as compared to placebo. However, the 60-day mortality rate of patients having received acyclovir was 22% vs. 33% for patients having received a placebo (delta = 11%, p=0.06). Moreover, in the subgroup of patients with 1 organ failure or less (organ failure being defined as a corresponding organ-SOFA (Sepsis-related Organ Failure Assessment) score of 3 or 4), 60-day mortality was significantly lower in patients receiving acyclovir (9%) than mortality of patients receiving placebo (30%, p =0.004). As mortality was not the primary endpoint of PTH study, these exploratory but promising results have yet to be formally confirmed. Therefore, the investigators aim to demonstrate that, in patients mechanically ventilated with HSV reactivation in the throat and 1 organ failure or less, pre-emptive treatment with acyclovir may decrease mortality.
This study is a multicenter, randomized, double-blind, placebo-controlled, concealed allocation superiority trial of intravenous acyclovir vs. placebo for mechanically ventilated patients with 1 organ failure or less and HSV reactivation in the throat. Patients ventilated >96 hours and without exclusion criteria will be screened twice weekly for HSV reactivation using quantitative PCR on swab collected in the throat.
Patients with HSV reactivation will be included and randomized into 2 groups (1:1): acyclovir or placebo. Patients will receive intravenous acyclovir or placebo during 14 days. To keep the blind design of the study, acyclovir and placebo will be reconstituted and/ diluted before the administration in saline bag by the pharmacy or a research's dedicated person (according to sites' possibilities) and dispensed to clinicians. Study drug will be stopped in patients discharged from ICU before end of treatment, i.e. if the patient is discharged before 14 days post randomization.
Allocation concealment will be centralized using a secure web-based randomization system. Patients will be reviewed daily in ICU, at hospital discharge and/or at day 60 post-randomization. Vital status, nosocomial bacterial and viral infection will be collected from day 1 to ICU discharge or day 60. Vital status will be collected at day 90. If discharged from hospital prior to 90 days, the patient (or substitute decision-maker if unable to communicate) will be contacted by telephone to determine the disposition and vital status.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Charles-Edouard LUYT, Pr
- Phone Number: +33 (0)142163824
- Email: charles-edouard.luyt@aphp.fr
Study Contact Backup
- Name: Anne BISSERY
- Phone Number: +33 (0)142162432
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged ≥ 18 year-old
- invasive mechanical ventilation(MV) for 96 hours and planned to last for at least 48 hours longer
- HSV reactivation in the throat (qualitative PCR positive for HSV on a throat swab)
- Presence of 1 or less organ failure; organ failure being defined as a corresponding-organ SOFA score of 3 or 4 (for example, renal failure will be defined as a renal SOFA score of 3 or 4)
- Effective contraception for patients of childbearing age, throughout the treatment period
- Written consent from the patient, from a close relative or from the person of trust previously appointed (or inclusion procedure in emergency situations)
- Under social security cover
Exclusion Criteria:
- Hypersensitivity to acyclovir and excipient
- Pregnant or breastfeeding (controlled by a blood pregnancy test)
- Patient who received an antiviral drug active against HSV (acyclovir, valacyclovir, gancyclovir, valgancyclovir, foscavir, cidofovir) in the previous 30 days
- Duration of ventilation before randomization >15 days
- Neutropenia, defined by an absolute neutrophils count < 1,000/mm3
- Solid organ or bone-marrow transplant
- Immunosuppressive treatment (including steroids at a dose >0.5 mg/kg/day of prednisone or equivalent for >1 month)
- HIV infection
- Moribund, defined by a Simplified Acute Physiology Score (SAPS) II score at inclusion >75 points
- Decision of withholding/withdrawing care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ACYCLOVIR
Intravenous acyclovir (ACYCLOVIR )
|
Patients randomized in the experimental arm will receive intravenous acyclovir at a dosing of 5 mg/kg/8 hours during 14 days (treatment will be stopped at ICU discharge).
|
Placebo Comparator: PLACEBO
saline bags
|
Patients randomized in the control arm will receive placebo, eg.
saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: day 60
|
Primary endpoint will be the mortality at day 60 post randomization
|
day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mortality
Time Frame: Vital status at day 90 will be assessed either by visit if the patient is still in the hospital, or by phone is the patient is discharged from the hospital
|
Day 90
|
Vital status at day 90 will be assessed either by visit if the patient is still in the hospital, or by phone is the patient is discharged from the hospital
|
Duration of mechanical ventilation
Time Frame: from date of randomization until the date of extubation or death, whichever first occurs, up to 60 days
|
Duration of mechanical ventilation, either invasive or non-invasive, from randomization to extubation or death, whichever first occurs
|
from date of randomization until the date of extubation or death, whichever first occurs, up to 60 days
|
Ventilator-free days at day 60
Time Frame: day 60 post-randomization
|
Measured as the number of day alive and without mechanical ventilation (invasive mechanical ventilation or non-invasive mechanical ventilation) from randomization to day 60 post-randomization.
Patients dying before day 60 will have zero ventilator-free days.
|
day 60 post-randomization
|
ICU length of stay
Time Frame: from date of randomization until the date of ICU discharge or death, up to 60 days
|
Measured by the number of day in the ICU from randomization to ICU discharge or death
|
from date of randomization until the date of ICU discharge or death, up to 60 days
|
ICU-free days
Time Frame: day 60 post-randomization
|
measured as the number of day alive and outside the ICU from randomization to day 60 post-randomization.
Patients dying before day 60 will have zero ICU-free days.
|
day 60 post-randomization
|
Hospital length of stay
Time Frame: from date of randomization until the date of hospital discharge or death, up to 60 days
|
Measured by the number of day in the hospital from randomization to hospital discharge or death
|
from date of randomization until the date of hospital discharge or death, up to 60 days
|
Hospital-free days
Time Frame: Day 60 post randomization
|
Measured as the number of day alive and outside the hospital from randomization to day 60 post-randomization.
Patients dying before day 60 will have zero ICU-free days.
|
Day 60 post randomization
|
Sepsis-related Organ Failure Assessment (SOFA) score (if patient is still hospitalized in ICU)
Time Frame: at days 1, 3, 5, 7, 10, 14, 21 and 28 post-randomization
|
This score will be collected using measures collected routinely in the ICU (clinical parameters, blood sampling) A score of two or more is associated with a 10% mortality risk in patients with suspected infection.
|
at days 1, 3, 5, 7, 10, 14, 21 and 28 post-randomization
|
Incidence of HSV oral-labial lesions
Time Frame: Oral-labial lesions suggestive of being due to HSV in patients randomized in the study will be recorded. These lesions will be sampled and samples will be sent to the virology laboratory, looking for HSV using polymerase chain reaction (PCR).
|
at day 28
|
Oral-labial lesions suggestive of being due to HSV in patients randomized in the study will be recorded. These lesions will be sampled and samples will be sent to the virology laboratory, looking for HSV using polymerase chain reaction (PCR).
|
Rate patient wth HSV positive in the throat
Time Frame: at days 3, 7, 10, 14, 17, 21 and 28 post randomization
|
at days 3, 7, 10, 14, 17, 21 and 28 post randomization
|
|
Rate of patient with HSV positive in the tracheal aspirate (if patient is still hospitalized in ICU)
Time Frame: at days 1, 7, 14, 21 and 28 post randomization
|
HSV viral load will be measure by quantitative PCR in tracheal aspirate at all time points.
Samples will be centralized and analyzed in the French national reference center for herpesviridae.
|
at days 1, 7, 14, 21 and 28 post randomization
|
Rate of HSV bronchopneumonitis
Time Frame: day 60 post randomization
|
HSV bronchopneumonitis will be defined by clinical signs suggestive of pneumonia, and presence of HSV in bronchoalveolar lavage (BAL) with a virus load > 105 copies/ millions of cells, whether or not patient had bacterial-viral (namely HSV and bacteria) co-infection.
|
day 60 post randomization
|
Rate of acute respiratory distress syndrome (ARDS)
Time Frame: day 60 post randomization
|
ARDS will be defined according to Berlin criteria .
Patients mechanically ventilated in the ICU have routinely chest X-ray and blood gases analyses, parameters needed to diagnose ARDS.
These parameters collected routinely will be used to define ARDS
|
day 60 post randomization
|
Rate of bacterial ventilator-associated pneumonia
Time Frame: day 60 post randomization
|
Ventilator-associated pneumonia will be defined as clinical signs suggestive of pneumonia, associated with a positive bacteriological sampling.
Episodes of ventilator-associated pneumonia will be collected from randomization to day 60.
|
day 60 post randomization
|
Rate of bacteremia
Time Frame: day 60 post randomization
|
Bacteremia will be defined as a single positive blood culture for pathogenic bacteria, or 2 different blood culture yielding the same pathogen for saprophytic bacteria.
Frequency and source of bacteremia will be recorded
|
day 60 post randomization
|
Glasgow coma scale (GCS) (if patient is still hospitalized in ICU)
Time Frame: at days 1, 3, 5, 7, 10, and 14 post-randomization.
|
Score range from 3 (completely unresponsive) to 15 (responsive) ; Lower GCS scores are correlated with higher risk of death
|
at days 1, 3, 5, 7, 10, and 14 post-randomization.
|
Creatinine clearance (if patient is still hospitalized in ICU)
Time Frame: at days 1, 3, 5, 7, 10, 14, 21 and 28 post randomization
|
at days 1, 3, 5, 7, 10, 14, 21 and 28 post randomization
|
|
Number of patients requiring renal replacement therapy
Time Frame: day 14 post randomization
|
day 14 post randomization
|
|
Renal replacement therapy- free days
Time Frame: day 14 post randomization
|
Measured as the number of day alive and without need for renal replacement therapy from randomization to day 14 post-randomization.
Patients dying before day 14 will have zero renal replacement therapy-free days
|
day 14 post randomization
|
Incidence of adverse event, severe adverse event
Time Frame: at days 1, 3, 5, 7, 10, 14, 21 and 28 post randomization
|
Intensity and frequency of adverse event and severe adverse event according to the WHO Toxicity Grading Scale for Determining The Severity of Adverse Events
|
at days 1, 3, 5, 7, 10, 14, 21 and 28 post randomization
|
Collaborators and Investigators
Investigators
- Principal Investigator: Charles-Edouard LUYT, Pr, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- APHP220800
- 2023-505510-26-00 (Other Identifier: CTIS)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Mechanical Ventilation
-
Henan Provincial People's HospitalNot yet recruitingInvasive Mechanical Ventilation
-
Chinese PLA General HospitalRecruiting
-
University Hospital, Strasbourg, FranceCompletedCritical Care | Invasive Mechanical VentilationFrance
-
Beijing Chao Yang HospitalRecruitingPatients Requiring Endotracheal Intubation and Invasive Mechanical VentilationChina
-
University of ChicagoNational Institute on Minority Health and Health Disparities (NIMHD)RecruitingEmpowerment | Children With Medical Complexity | Invasive Mechanical Ventilation | Home NursingUnited States
-
Ege UniversityCompleted
-
Far Eastern Memorial HospitalCompletedMechanical Ventilation | Hospital Length of Stay | Minimally Invasive Cardiac SurgeryTaiwan
-
Unity Health TorontoCompletedCritical Illness | Tracheostomy | Spontaneous Breathing Trial | Invasive Mechanical Ventilation | Weaning Invasive Mechanical Ventilation | Direct ExtubationUnited States, Canada
-
Technische Universität DresdenRecruitingInvasive Mechanical VentilationSwitzerland, Germany, Spain, United States, Serbia
-
University Hospital, MontpellierCompletedIntensive Care Unit | Invasive Mechanical VentilationFrance
Clinical Trials on Intravenous acyclovir (ACYCLOVIR )
-
King Edward Medical UniversityCompletedHerpes Virus InfectionPakistan
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)Completed
-
University of WashingtonNational Institutes of Health (NIH)Completed
-
National Center for Research Resources (NCRR)National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Centers for Disease Control and PreventionMinistry of Health, ThailandCompleted
-
National Center for Research Resources (NCRR)University of Alabama at BirminghamCompletedHerpes SimplexUnited States, Canada
-
National Center for Research Resources (NCRR)National Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHerpes SimplexUnited States
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID)Terminated
-
University of WashingtonNational Institutes of Health (NIH)CompletedGenital HerpesUnited States